Zymeworks Appoints Computational Antibody Design Expert Dr. Bruce Tidor to its Scientific Advisory Board

VANCOUVER, British Columbia--(Business Wire)--
Zymeworks Inc., a privately held computational biotechnology company, today
announced the appointment of Dr. Bruce Tidor, Professor in the Departments of
Biological Engineering and of Electrical Engineering and Computer Science at the
Massachusetts Institute of Technology (MIT), to its scientific advisory board.

"Dr. Tidor is renowned in academia and industry for his use of leading-edge
computational methodologies to understand and engineer protein therapeutics,"
says Dr. Ali Tehrani, President and CEO of Zymeworks. "His unique
cross-disciplinary blend of expertise and vision in modeling and biochemistry
will be invaluable to Zymeworks` ongoing technology refinement in rational
protein optimization and engineering."

Dr. Bruce Tidor is Professor of Biological Engineering and Computer Science and
is a member of the Computer Science and Artificial Intelligence Laboratory at
MIT. With over 100 peer-reviewed publications, Dr. Tidor`s prolific research
centers on the use of molecular modeling and computation to understand protein
and nucleic acid structures, functions, and interactions. One of his recent
highly regarded studies described the use of rational design to optimize
monoclonal antibodies Avastin and Erbitux, leading to the opportunity to use
similar approaches to develop second-generation protein therapeutics. Dr. Tidor
graduated summa cum laude with an A.B. in Chemistry and Physics from Harvard
College, earned a M.Sc. in Biochemistry at Oxford University`s Wolfson College
as a Marshall Scholar, and received his Ph.D. in Biophysics from Harvard. He was
a Whitehead Fellow at the Whitehead Institute for Biomedical Research and
currently serves as the founding co-Director of MIT`s Computational and Systems
Biology Initiative.

About Zymeworks Inc.

Zymeworks is a computational biotechnology company researching and developing
next-generation protein therapeutics. Zymeworks leverages proprietary insight
into structure-function relationships generated by the ZymeCAD platform to
optimize the efficacy and potency of protein therapeutics. Zymeworks is focused
on developing a biotherapeutics pipeline through strategic collaborations and
internal research programs. More information on Zymeworks can be found at
http://www.zymeworks.com.

Zymeworks Inc.
David Poon, Ph.D., 604-678-1388
Manager, Business Development
info@zymeworks.com

Copyright Business Wire 2009